Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer

The development of new therapies that can prevent recurrence and progression of nonmuscle invasive bladder cancer remains an unmet clinical need. The continued cost of monitoring and treatment of recurrent disease, along with its high prevalence and incidence rate, is a strain on healthcare economic...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuji, Shingo, Chen, Xuguang, Hancock, Bryan, Hernandez, Veronica, Visentin, Barbara, Reil, Katherine, Sabbadini, Roger, Giacalone, Matthew, Godbey, WT
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824562/
https://www.ncbi.nlm.nih.gov/pubmed/27119118
http://dx.doi.org/10.1038/mto.2016.4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824562/
https://www.ncbi.nlm.nih.gov/pubmed/27119118
http://dx.doi.org/10.1038/mto.2016.4

Ejemplares similares